Brucellosis is an important bacterial disease of livestock and the most common zoonotic disease. The current vaccines are effective but unsafe, as they result in animal abortions and are pathogenic to humans. Virus-like particles are being investigated as molecular scaffolds for foreign antigen presentation to the immune system. Here, we sought to develop a new-generation vaccine by presenting selected T cell epitopes on the surface of Orbivirus core-like particles (CLPs) and transiently expressing these chimeric particles in plants. We successfully demonstrated the assembly of five chimeric CLPs in plants, with each CLP presenting a different T cell epitope. The safety and protective efficacy of three of th... More
Brucellosis is an important bacterial disease of livestock and the most common zoonotic disease. The current vaccines are effective but unsafe, as they result in animal abortions and are pathogenic to humans. Virus-like particles are being investigated as molecular scaffolds for foreign antigen presentation to the immune system. Here, we sought to develop a new-generation vaccine by presenting selected T cell epitopes on the surface of Orbivirus core-like particles (CLPs) and transiently expressing these chimeric particles in plants. We successfully demonstrated the assembly of five chimeric CLPs in plants, with each CLP presenting a different T cell epitope. The safety and protective efficacy of three of the highest-yielding CLPs was investigated in a mouse model of brucellosis. All three plant-expressed chimeric CLPs were safe when inoculated into BALB/c mice at specific antigen doses. However, only one chimeric CLP induced protection against the virulent strain challenge equivalent to the protection induced by the commercial Rev1 vaccine. Here, we have successfully shown the assembly, safety and protective efficacy of plant-expressed chimeric CLPs presenting T cell epitopes. This is the first step in the development of a safe and efficacious subunit vaccine against brucellosis.
